trending Market Intelligence /marketintelligence/en/news-insights/trending/2p5GBqYZEENdc5yUmOxbxg2 content esgSubNav
In This List

FibroGen plans follow-on offering of common stock

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


FibroGen plans follow-on offering of common stock

FibroGen Inc. plans to offer and sell up to $300 million of its common stock in an underwritten follow-on offering.

The company expects to grant the underwriters an option to buy additional common shares.

Net proceeds will be used to fund the expansion of product development, manufacturing and commercialization activities as well as for general corporate purposes.

Goldman Sachs & Co. LLC, Citigroup and Leerink Partners LLC are acting as joint book-running managers for the offering.